Myriad outlines $780M-$790M 2026 revenue outlook following $210M Prenatal Health divestiture deal (NASDAQ:MYGN)
Myriad Genetics (MYGN) has set a 2026 revenue outlook of $780M-$790M after divesting its Prenatal Health business for $210M. The company acknowledges challenges in Prenatal Health and reimbursement pressures in HCT, and is taking actions to address them.
How this was made
The 30-second read
Why it matters
The guidance and divestiture signal a strategic shift that may affect valuation multiples.
Market read
Guidance and divestiture are primary news for Myriad, likely influencing its stock price in the short term.
What to watch
Possible cost synergies from the sale and reinvestment of proceeds into core oncology pipelines.
Background
Myriad Genetics provided its Q3 2026 outlook and announced the sale of its Prenatal Health unit.
Ticker impact
Myriad Genetics disclosed a 2026 revenue outlook of $780M-$790M after a $210M Prenatal Health divestiture.
downward pressure as investors price in lower-than-expected revenue and the loss of the Prenatal Health segment
The new revenue range is modest and the $210M divestiture reduces future cash flow, which typically leads to a negative market reaction.
Market effects
Potential re‑rating of the genetic testing sector as Myriad trims its Prenatal Health business.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond Myriad and its direct competitors.
Counterpoint
The divestiture could sharpen focus on higher‑margin segments, offering upside if execution improves.
Key entities
- companyMyriad Genetics
US‑listed genetic testing firm (NASDAQ:MYGN).
